Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-701 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-701
Tmax of ABBV-701
(β) of ABBV-701
(t1/2) of ABBV-701
AUCt of ABBV-701
AUCinf of ABBV-701
| Arm | Type | Description |
|---|---|---|
| Part 1: Group 1 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose A or placebo. |
| Part 1: Group 2 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose B or placebo. |
| Part 1: Group 3 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose C or placebo. |
| Part 1: Group 4 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose D or placebo. |
| Part 1: Group 5 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 2: Group 6 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 2: Group 7 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 3: Group 8 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose C or placebo. |
| Part 3: Group 9 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 3: Group 10 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Part 4: Group 11 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Part 4: Group 12 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-701 | DRUG | Subcutaneous |
| Placebo | DRUG | Subcutaneous |
Inclusion Criteria: * Body weight is ≥ 35 kg and BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG * Part 2 and Part 4 only:...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Duvakitug, balinatunfib, Brivekimig |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
ABBV-701 is an investigational small molecule being developed by AbbVie Inc. for Crohn's disease. It is currently in Phase 1 clinical development, meaning it has not been approved by the FDA and remains under study. Only one clinical trial of ABBV-701 has been recorded to date.
ABBV-701 is being developed as a potential treatment for Crohn's disease, an inflammatory condition of the digestive tract. It is investigational and has not been approved for any indication. The only trial recorded for ABBV-701 so far enrolled healthy adult volunteers rather than patients with Crohn's disease.
ABBV-701 is developed by AbbVie Inc., the pharmaceutical company that trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the ABBV-701 clinical program, which is currently at the Phase 1 stage of development.
ABBV-701 is in Phase 1 clinical development. It is an investigational small molecule and is not FDA approved. The Phase 1 program consists of one active trial that is no longer recruiting participants, and no trials of ABBV-701 have been completed.
ABBV-701 is being studied in one Phase 1 trial, NCT06895343, titled a study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending subcutaneous or intravenous doses of ABBV-701 in healthy adult Western and Asian participants. The trial is active but not recruiting, enrolled 100 participants, and is conducted in the United States.
Yes. The Phase 1 trial of ABBV-701, NCT06895343, is a randomized, double-blind, controlled study. It enrolled 100 healthy adult volunteers aged 18 years and older of all sexes, and it evaluates single ascending subcutaneous or intravenous doses of ABBV-701 in Western and Asian participants.